Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

pembrolizumab 20Cisplatin 17Cetuximab 13Docetaxel 11Paclitaxel 9Carboplatin 9Radiotherapy 8Fluorouracil 6cemiplimab 5130-nm albumin-bound paclitaxel 5Bleomycin 4Radiation 3Pemetrexed 3Panitumumab 3Nivolumab 3Gemcitabine 3Albumin-Bound Paclitaxel 3vandetanib 2talimogene laherparepvec 2selinexor 2motexafin gadolinium 2figitumumab 2brigatinib 2avelumab 2atezolizumab 2alpha-2'-deoxythioguanosine 2advexin 2Taxes 2ON 01910 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Squamous Cell × nedaplatin × Clear all
NCT02088515 2017-03-03

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 4 Completed
290 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡